Proteus vulgaris: Difference between revisions
(Created page with "==Background== ==Antibiotic Sensitivities<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>== {| class="wikitable" | align="center" style="background:#f0f0f0;"|'''Cat...") |
|||
| Line 17: | Line 17: | ||
| ||[[Cloxacillin]]/[[Diclox.]]||R | | ||[[Cloxacillin]]/[[Diclox.]]||R | ||
|- | |- | ||
| Amino-[[Penicillins]]||[[AMP]]/[[Amox]]|| | | Amino-[[Penicillins]]||[[AMP]]/[[Amox]]||R | ||
|- | |- | ||
| ||[[Amox-Clav]]||'''S''' | | ||[[Amox-Clav]]||'''S''' | ||
| Line 51: | Line 51: | ||
| ||[[Moxifloxacin]]||'''S''' | | ||[[Moxifloxacin]]||'''S''' | ||
|- | |- | ||
| ||[[Gemifloxacin]]|| | | ||[[Gemifloxacin]]||'''S''' | ||
|- | |- | ||
| ||[[Gatifloxacin]]||'''S''' | | ||[[Gatifloxacin]]||'''S''' | ||
|- | |- | ||
| 1st G [[Cephalo]]||[[Cefazolin]]|| | | 1st G [[Cephalo]]||[[Cefazolin]]||R | ||
|- | |- | ||
| 2nd G. [[Cephalo]]||[[Cefotetan]]||'''S''' | | 2nd G. [[Cephalo]]||[[Cefotetan]]||'''S''' | ||
| Line 75: | Line 75: | ||
| ||[[Cefepime]]||'''S''' | | ||[[Cefepime]]||'''S''' | ||
|- | |- | ||
| Oral 1st G. [[Cephalo]]||[[Cefadroxil]]|| | | Oral 1st G. [[Cephalo]]||[[Cefadroxil]]||R | ||
|- | |- | ||
| ||[[Cephalexin]]|| | | ||[[Cephalexin]]||R | ||
|- | |- | ||
| Oral 2nd G. [[Cephalo]]||[[Cefaclor]]/[[Loracarbef]]|| | | Oral 2nd G. [[Cephalo]]||[[Cefaclor]]/[[Loracarbef]]||R | ||
|- | |- | ||
| ||[[Cefproxil]]|| | | ||[[Cefproxil]]||R | ||
|- | |- | ||
| ||[[Cefuroxime axetil]]|| | | ||[[Cefuroxime axetil]]||R | ||
|- | |- | ||
| Oral 3rd G. [[Cephalo]]||[[Cefixime]]||'''S''' | | Oral 3rd G. [[Cephalo]]||[[Cefixime]]||'''S''' | ||
| Line 89: | Line 89: | ||
| ||[[Ceftibuten]]||'''S''' | | ||[[Ceftibuten]]||'''S''' | ||
|- | |- | ||
| ||[[Cefpodox]]/[[Cefdinir]]/[[Cefditoren]]|| | | ||[[Cefpodox]]/[[Cefdinir]]/[[Cefditoren]]||I | ||
|- | |- | ||
| [[Aminoglycosides]]||[[Gentamicin]]|| | | [[Aminoglycosides]]||[[Gentamicin]]||'''S''' | ||
|- | |- | ||
| ||[[Tobramycin]]|| | | ||[[Tobramycin]]||'''S''' | ||
|- | |- | ||
| ||[[Amikacin]]|| | | ||[[Amikacin]]||'''S''' | ||
|- | |- | ||
| ||[[Chloramphenicol]]|| | | ||[[Chloramphenicol]]||I | ||
|- | |- | ||
| ||[[Clindamycin]]|| | | ||[[Clindamycin]]||R | ||
|- | |- | ||
| [[Macrolides]]||[[Erythromycin]]|| | | [[Macrolides]]||[[Erythromycin]]||R | ||
|- | |- | ||
| ||[[Azithromycin]]|| | | ||[[Azithromycin]]||R | ||
|- | |- | ||
| ||[[Clarithromycin]]|| | | ||[[Clarithromycin]]||R | ||
|- | |- | ||
| Ketolide||[[Telithromycin]]|| | | Ketolide||[[Telithromycin]]||R | ||
|- | |- | ||
| Tetracyclines||[[Doxycycline]]|| | | Tetracyclines||[[Doxycycline]]||R | ||
|- | |- | ||
| ||[[Minocycline]]|| | | ||[[Minocycline]]||R | ||
|- | |- | ||
| Glycylcycline||[[Tigecycline]]|| | | Glycylcycline||[[Tigecycline]]||I | ||
|- | |- | ||
| ||[[Daptomycin]]|| | | ||[[Daptomycin]]||R | ||
|- | |- | ||
| Glyco/Lipoclycopeptides||[[Vancomycin]]|| | | Glyco/Lipoclycopeptides||[[Vancomycin]]||R | ||
|- | |- | ||
| ||[[Teicoplanin]]|| | | ||[[Teicoplanin]]||R | ||
|- | |- | ||
| ||[[Telavancin]]|| | | ||[[Telavancin]]||R | ||
|- | |- | ||
| ||[[Fusidic Acid]]|| | | ||[[Fusidic Acid]]||R | ||
|- | |- | ||
| ||[[Trimethoprim]]|| | | ||[[Trimethoprim]]||R | ||
|- | |- | ||
| ||[[TMP-SMX]]|| | | ||[[TMP-SMX]]||R | ||
|- | |- | ||
| Urinary Agents||[[Nitrofurantoin]]|| | | Urinary Agents||[[Nitrofurantoin]]||R | ||
|- | |- | ||
| ||[[Fosfomycin]]|| | | ||[[Fosfomycin]]||'''S''' | ||
|- | |- | ||
| Other||[[Rifampin]]|| | | Other||[[Rifampin]]||R | ||
|- | |- | ||
| ||[[Metronidazole]]|| | | ||[[Metronidazole]]||R | ||
|- | |- | ||
| ||[[Quinupristin dalfoppristin]]||X1 | | ||[[Quinupristin dalfoppristin]]||X1 | ||
|- | |- | ||
| ||[[Linezolid]]|| | | ||[[Linezolid]]||R | ||
|- | |- | ||
| ||[[Colistimethate]]|| | | ||[[Colistimethate]]||R | ||
|} | |} | ||
Latest revision as of 02:08, 24 June 2014
Background
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
Table Overview
| ||||||||||||||||||||||||||||||||||||||||
See Also
References
- ↑ Sanford Guide to Antimicrobial Therapy 2014
